# EDGAR Filing Document

**Accession Number:** 0001849296
**File Stem:** 0001493152-23-001588
**Filing Date:** 2023-1
**Character Count:** 2026
**Document Hash:** 51d88cb6d77f7a8ac92e7cbe40066763
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-001588.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0001493152-23-001588

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230117

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OKYO Pharma Ltd
- **CENTRAL INDEX KEY:** 0001849296
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 55 PARK LANE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1K 1NA
- **BUSINESS PHONE:** 44 (0) 207 495 2379

**MAIL ADDRESS:**
- **STREET 1:** 55 PARK LANE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1K 1NA

**OKYO Pharma Ltd.**

**Martello Court** 

**Admiral Park**

**St. Peter Court**

**Guernsey GY1 3HB**

January 17, 2023

**<u>VIA EDGAR</u>**

United States Securities

and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Tyler Howes

---

| | |
|:---|:---|
| **Re:** | **OKYO Pharma Ltd.** |
|  | **Registration Statement on Form F-1/A** |
|  | **File No. 333-268675** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the "Act"), OKYO Pharma Ltd. (the "Company") respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:00 p.m., Eastern Standard Time, on Thursday, January 19, 2023, or as soon thereafter as practicable.

Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

---

| | |
|:---|:---|
| Thank you, | Thank you, |
| **OKYO PHARMA LTD.** | **OKYO PHARMA LTD.** |
| By: | */s/ Gary S. Jacob* |
| **Name:** | **Gary S. Jacob** |
| Title: | Chief Executive Officer |

---